Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria

Oche Agbaji*, Chloe L. Thio, Seema Meloni, Camilla Graham, Mohammed Muazu, Ladep Nimzing, John Idoko, Jean Louis Sankalé, Ernest Ekong, Robert Murphy, Phyllis Kanki, Claudia Hawkins

*Corresponding author for this work

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

The effect of hepatitis C virus (HCV) on antiretroviral therapy (ART) response in patients in sub-Saharan Africa is unknown. We studied 1431 HIV-infected ART initiators in Jos, Nigeria, of whom 6% were HCV coinfected. A similar proportion of HIV/HCV-coinfected and HIV-monoinfected patients achieved HIV RNA <400 copies per milliliter after 24 and 48 weeks of ART (P > 0.05). Hepatotoxicity was uncommon (0.8% and 0.33% at 24 and 48 weeks, respectively) but was more common in the HIV/HCV-coinfected group at 24 (adjusted odds ratio = 19.3; 95% confidence interval: 4.41 to 84.4) and 48 weeks (adjusted odds ratio = 56.7; 95% confidence interval: 5.03 to 636.92). HCV did not significantly impact ART response in this Nigerian cohort.

Original languageEnglish (US)
Pages (from-to)204-207
Number of pages4
JournalJournal of Acquired Immune Deficiency Syndromes
Volume62
Issue number2
DOIs
StatePublished - Feb 1 2013

Keywords

  • Africa
  • HIV
  • antiretroviral therapy
  • hepatitis C

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria'. Together they form a unique fingerprint.

  • Cite this

    Agbaji, O., Thio, C. L., Meloni, S., Graham, C., Muazu, M., Nimzing, L., Idoko, J., Sankalé, J. L., Ekong, E., Murphy, R., Kanki, P., & Hawkins, C. (2013). Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria. Journal of Acquired Immune Deficiency Syndromes, 62(2), 204-207. https://doi.org/10.1097/QAI.0b013e31827ce536